Current and future antihypertensive drugs in post-transplant hypertension and related patents

Bibliography

• CHOBANIAN AV, BAKRIS GL, BLACK HR et al.; JOINT NATIONAL COMMITTEE ON PREVENTION, DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD PRESSURE. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE; NATIONAL HIGH BLOOD PRESSURE. EDUCATION PROGRAM COORDINATING COMMITTEE: Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. (2003) 42(6):1206-1252.
   PubMed Web of Science ®Google Scholar
• TOTO RD: Treatment of hypertension in chronic kidney disease. Semin. Nephrol. (2005) 25(6):435-439.
   PubMed Web of Science ®Google Scholar
• LOCATELLI F, COVIC A, CHAZOT C, LEUNISSEN K, LUNO J, YAQOOB M; ACCORDE PROGRAMME: Hypertension and cardiovascular risk assessment in dialysis patients. Nephrol. Dial. Transplant. (2004) 19(5):1058-1068.
   PubMedGoogle Scholar
• KASISKE BL, ANJUM S, SHAH R et al.: Hypertension after kidney transplantation. Am. J. Kidney. Dis. (2004) 43(6):1071-1081.
   PubMed Web of Science ®Google Scholar
• FIRST MR, NEYLAN JF, ROCHER LL, TEJANI A: Hypertension after renal transplantation. J. Am. Soc. Nephrol. (1994) 4(8 Suppl):S30-S36.
   PubMed Web of Science ®Google Scholar
• ZEIER M, MANDELBAUM A, RITZ E: Hypertension in the transplanted patient. Nephron. (1998) 80(3):257-268.
   PubMedGoogle Scholar
• MIDTVEDT K, HARTMANN A: Hypertension after kidney transplantation: are treatment guidelines emerging? Nephrol. Dial. Transplant. (2002) 17(7):1166-1169.
   PubMed Web of Science ®Google Scholar
• OPELZ G, WUJCIAK T, RITZ E: Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney. Int. (1998) 53(1):217-222.
   PubMedGoogle Scholar
• TYLICKI L, HABICHT A, WATSCHINGER B, HORL WH: Treatment of hypertension in renal transplant recipients. Curr. Opin. Urol. (2003) 13(2):91-98.
   PubMedGoogle Scholar
• CASTILLO-LUGO JA, VERGNE-MARINI P: Hypertension in kidney transplantation. Semin. Nephrol. (2005) 25(4):252-260.
   PubMedGoogle Scholar
• RUGGENENTI P, PERICO N, MOSCONI L et al.: Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney. Int. (1993) 43(3):706-711.
   PubMed Web of Science ®Google Scholar
• MCCULLOCH TA, HARPER SJ, DONNELLY PK et al.: Influence of nifedipine on interstitial fibrosis in renal transplant allografts treated with cyclosporin A. J. Clin. Pathol. (1994) 47(9):839-842.
   PubMedGoogle Scholar
• BIRX DL, BERGER M, FLEISHER TA: The interference of T cell activation by calcium channel blocking agents. J. Immunol. (1984) 133(6):2904-2909.
   PubMed Web of Science ®Google Scholar
• RAHN KH, BARENBROCK M, FRITSCHKA E et al.: Effect of nitrendipine on renal function in renal-transplant patients treated with cyclosporin: a randomised trial. Lancet. (1999) 354(9188):1415-1420.
   PubMedGoogle Scholar
• LADEFOGED SD, ANDERSEN CB: Calcium channel blockers in kidney transplantation. Clin. Transplant. (1994) 8(2 Pt 1):128-133.
   PubMed Web of Science ®Google Scholar
• VAN DER SCHAAF MR, HENE RJ, FLOOR M, BLANKESTIJN PJ, KOOMANS HA: Hypertension after renal transplantation. Calcium channel or converting enzyme blockade? Hypertension. (1995) 25(1):77-81.
   PubMedGoogle Scholar
• MIDTVEDT K, HARTMANN A, FOSS A et al.: Sustained improvement of renal graft function for 2 years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation. (2001) 72(11):1787-1792.
   PubMedGoogle Scholar
• MIDTVEDT K, IHLEN H, HARTMANN A et al.: Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: a prospective randomized double-blind study. Transplantation (2001) 72(1):107-111.
   PubMed Web of Science ®Google Scholar
• MOURAD G, RIBSTEIN J, MIMRAN A: Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. Kidney Int. (1993) 43(2):419-425.
   PubMedGoogle Scholar
• KLOKE HJ, WETZELS JF, KOENE RA, HUYSMANS FT: Effects of low-dose nifedipine on urinary protein excretion rate in patients with renal disease. Nephrol. Dial. Transplant. (1998) 13(3):646-650.
   PubMedGoogle Scholar
• KOSTIS JB: Treatment of hypertension in older patients: an updated look at the role of calcium antagonists. Am. J. Geriatr. Cardiol. (2003) 12(5):319-327.
   PubMedGoogle Scholar
• WENZEL RR: Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs (2005) 65(Suppl 2):29-39.
   PubMed Web of Science ®Google Scholar
• MCKEAGE K, SCOTT LJ: Manidipine: a review of its use in the management of hypertension. Drugs (2004) 64(17):1923-1940
   PubMed Web of Science ®Google Scholar
• MAZZALI M: Uric acid and transplantation. Semin. Nephrol. (2005) 25(1):50-55.
   PubMed Web of Science ®Google Scholar
• CHANARD J, TOUPANCE O, LAVAUD S, HURAULT DE LIGNY B, BERNAUD C, MOULIN B: Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients. Nephrol. Dial. Transplant. (2003) 18(10):2147-2153.
   PubMed Web of Science ®Google Scholar
• KHOORI AH, EINOLLAHI B, ANSARI G, MOOZEH MB: The effect of cyclosporine with and without nifedipine on gingival overgrowth in renal transplant patients. Can. Dent. Assoc. (2003) 69(4):236-241.
   PubMedGoogle Scholar
• PESAVENTO TE, JONES PA, JULIAN BA, CURTIS JJ: Amlodipine increases cyclosporine levels in hypertensive renal transplant patients: results of a prospective study. J. Am. Soc. Nephrol. (1996) 7(6):831-835.
   PubMed Web of Science ®Google Scholar
• KAPLAN NM: Calcium entry blockers in the treatment of hypertension. Current status and future prospects. JAMA (1989) 262(6):817-823
   PubMed Web of Science ®Google Scholar
• ISRAILI ZH, HALL WD: Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann. Intern. Med. (1992) 117(3):234-242.
   PubMedGoogle Scholar
• REMUZZI G, PERICO N: Routine renin-angiotensin system blockade in renal transplantation? Curr. Opin. Nephrol. Hypertens. (2002) 11(1):1-10.
   PubMedGoogle Scholar
• ROBINS GW, SCOTT LJ: Eprosartan: a review of its use in the management of hypertension. Drugs (2005) 65(16):2355-2377.
   PubMed Web of Science ®Google Scholar
• STIGANT CE, COHEN J, VIVERA M, ZALTZMAN JS: ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy. Am. J. Kidney Dis. (2000) 35(1):58-63.
   PubMed Web of Science ®Google Scholar
• DEL CASTILLO D, CAMPISTOL JM, GUIRADO L et al.: Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int. Suppl. (1998) 68:S135-S139.
   PubMedGoogle Scholar
• INIGO P, CAMPISTOL JM, SARACHO R et al.: Renoprotective effects of losartan in renal transplant recipients. Results of a retrospective study. Nephron. Clin. Pract. (2003) 95(3):c84-c90.
   Google Scholar
• TYLICKI L, RUTKOWSKI P, RENKE M, RUTKOWSKI B: Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Short-term observation. Am. J. Nephrol. (2002) 22(4):356-362.
   PubMed Web of Science ®Google Scholar
• USTA M, ERSOY A, DILEK K et al.: Efficacy of losartan in patients with primary focal segmental glomerulosclerosis resistant to immunosuppressive treatment. J. Intern. Med. (2003) 253(3):329-334.
   PubMed Web of Science ®Google Scholar
• MATTEUCCI E, CARMELLINI M, BERTONI C, BOLDRINI E, MOSCA F, GIAMPIETRO O: Urinary excretion rates of multiple renal indicators after kidney transplantation: clinical significance for early graft outcome. Ren. Fail. (1998) 20(2):325-330.
   PubMed Web of Science ®Google Scholar
• SUWELACK B, KOBELT V, ERFMANN M et al.: Long-term follow-up of ACE-inhibitor versus β-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients. Transpl. Int. (2003) 16(5):313-320.
   PubMed Web of Science ®Google Scholar
• ERSOY A, DILEK K, USTA M et al.: Angiotensin-II receptor antagonist losartan reduces microalbuminuria in hypertensive renal transplant recipients. Clin. Transplant. (2002) 16(3):202-205.
   PubMed Web of Science ®Google Scholar
• SZABO A, LUTZ J, SCHLEIMER K et al.: Effect of angiotensin-converting enzyme inhibition on growth factor mRNA in chronic renal allograft rejection in the rat. Kidney Int. (2000) 57(3):982-991.
   PubMed Web of Science ®Google Scholar
• INIGO P, CAMPISTOL JM, LARIO S et al.: Effects of losartan and amlodipine on intrarenal hemodynamics and TGF-β(1) plasma levels in a crossover trial in renal transplant recipients. J. Am. Soc. Nephrol. (2001) 12(4):822-827.
   PubMed Web of Science ®Google Scholar
• HETZEL GR, HERMSEN D, HOHLFELD T et al.: Effects of candesartan and perindopril on renal function, TGF-β1 plasma levels and excretion of prostaglandins in stable renal allograft recipients. Clin. Nephrol. (2002) 57(4):296-302.
   PubMedGoogle Scholar
• HETZEL GR, PLUM J, FUSSHOLLER A, VOICULESCU A, GRUNBERG W, GRABENSEE B: Effects of candesartan on glomerular hemodynamics and permselectivity in patients with favorable renal allograft function. Transplantation (2005) 79(6):710-715.
   PubMedGoogle Scholar
• OMOTO K, TANABE K, TOKUMOTO T, SHIMMURA H, ISHIDA H, TOMA H: Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction. Transplantation (2003) 76(8):1170-1174.
   PubMed Web of Science ®Google Scholar
• ISHIKAWA A, OHTA N, OZONO S, KAWABE K, KITAMURA T: Inhibition of plasminogen activator inhibitor-1 by angiotensin II receptor blockers on cyclosporine-treated renal allograft recipients. Transplant. Proc. (2005) 37(2):994-996.
   PubMedGoogle Scholar
• ZALTZMAN JS, NASH M, CHIU R, PRASAD R: The benefits of renin–angiotensin blockade in renal transplant recipients with biopsy-proven allograft nephropathy. Nephrol. Dial. Transplant. (2004) 19(4):940-944.
   PubMedGoogle Scholar
• LIN J, VALERI AM, MARKOWITZ GS, D'AGATI VD, COHEN DJ, RADHAKRISHNAN J: Angiotensin converting enzyme inhibition in chronic allograft nephropathy. Transplantation (2002) 73(5):783-788.
   PubMedGoogle Scholar
• HERNANDEZ D, LACALZADA J, SALIDO E et al.: Regression of left ventricular hypertrophy by lisinopril after renal transplantation: role of ACE gene polymorphism. Kidney. Int. (2000) 58(2):889-897.
   PubMedGoogle Scholar
• AHMAD T, COULTHARD MG, EASTHAM EJ: Reversible renal failure due to the use of captopril in a renal allograft recipient treated with cyclosporin. Nephrol. Dial. Transplant. (1989) 4(4):311-312.
   PubMedGoogle Scholar
• LORENZ M, BILLENSTEINER E, BODINGBAUER M, OBERBAUER R, HORL WH, HAAS M: The effect of ACE inhibitor and angiotensin II blocker therapy on early posttransplant kidney graft function. Am. J. Kidney. Dis. (2004) 43(6):1065-1070.
   PubMedGoogle Scholar
• ERSOY A, KAHVECİOGLU S, ERSOY C, CIFT A, DILEK K: Anemia due to losartan in hypertensive renal transplant recipients without posttransplant erythrocytosis. Trans. Proc. (2005) 37(5):2148-2150.
   PubMedGoogle Scholar
• ELLIOTT WJ: Traditional drug therapy of hypertension in transplant recipients. J. Hum. Hypertens. (1998) 12(12):845-849.
   PubMedGoogle Scholar
• OLYAEI AJ, DEMATTOS AM, BENNETT WM: A practical guide to the management of hypertension in renal transplant recipients. Drugs (1999) 58(6):1011-1027.
   PubMed Web of Science ®Google Scholar
• BELL DS: Advantages of a third-generation β-blocker in patients with diabetes mellitus. Am. J. Cardiol. (2004) 93(9A):49B-52B.
   Google Scholar
• ZEZINA L, VESSBY B, LARSSON E, BACKMAN U, FELLSTROM B: Carvedilol treatment of kidney graft recipients with chronic rejection. Clin. Transplant. (1999) 13(6):484-490.
   PubMedGoogle Scholar
• WONG VY, LAPING NJ, NELSON AH et al.: Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF β expression. Br. J. Pharmacol. (2001) 134(5):977-984.
   PubMed Web of Science ®Google Scholar
• PAUL LC: Chronic allograft nephropathy: An update. Kidney. Int. (1999) 56(3):783-793.
   PubMed Web of Science ®Google Scholar
• YASUNARI K, MAEDA K, NAKAMURA M, WATANABE T, YOSHIKAWA J, ASADA A: Effects of carvedilol on oxidative stress in polymorphonuclear and mononuclear cells in patients with essential hypertension. Am. J. Med. (2004) 116(7):460-465.
   PubMed Web of Science ®Google Scholar
• CALO L, GIACON B, DAVIS PA et al.: Oxidative stress and TGFβ in kidney-transplanted patients with cyclosporin-induced hypertension. Effect of carvedilol and nifedipine. Clin. Nephrol. (2002) 58(2):103-110.
   PubMedGoogle Scholar
• STROJEK K, GRZESZCZAK W, GORSKA J, LESCHINGER MI, RITZ E: Lowering of microalbuminuria in diabetic patients by a sympathicoplegic agent: novel approach to prevent progression of diabetic nephropathy? Am. Soc. Nephrol. (2001) 12(3):602-605.
   PubMedGoogle Scholar
• MARTINEZ-CASTELAO A, HUESO M, SANZ V, REJAS J, ALSINA J, GRINYO JM: Treatment of hypertension after renal transplantation: long-term efficacy of verapamil, enalapril, and doxazosin. Kidney Int. Suppl. (1998) 68:S130-S134.
   PubMedGoogle Scholar
• ALLHAT OFFICERS AND COORDINATORS FOR THE ALLHAT COLLABORATIVE RESEARCH GROUP: The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. (2002) 288(23):2981-2997.
   PubMed Web of Science ®Google Scholar
• COGOLLUDO A, PEREZ-VIZCAINO F, TAMARGO J: New insights in the pharmacological therapy of arterial hypertension. Curr. Opin. Nephrol. Hypertens. (2005) 14(5):423-427.
   PubMedGoogle Scholar
• KHANNA JM: Azelnidipine (Sankyov KK). IDrugs (1999) 2(8):807-813.
   PubMedGoogle Scholar
• WELLINGTON K, SCOTT LJ: Azelnidipine. Drugs (2003) 63(23):2613-2621.
   PubMed Web of Science ®Google Scholar
• OHMORI M, ARAKAWA M, HARADA K et al.: Stereoselective pharmacokinetics of amlodipine in elderly hypertensive patients. Am. J. Ther. (2003) 10(1):29-31.
   PubMedGoogle Scholar
• PATHAK L, HIREMATH, KERKAR PG, MANADE VG: Multicentric, clinical trial of S-amlodipine 2.5 mg versus amlodipine 5 mg in the treatment of mild to moderate hypertension – a randomized, double-blind clinical trial. Assoc. Physicians. India. (2004) 52:197-202.
   PubMedGoogle Scholar
• STANTON A: Therapeutic potential of renin inhibitors in the management of cardiovascular disorders. Am. J. Cardiovasc. Drugs. (2003) 3:389-394.
   PubMedGoogle Scholar
• RAHUEL J, RASETTI V, MAIBAUM J et al.: Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Chem. Biol. (2000) 7(7):493-504.
   PubMed Web of Science ®Google Scholar
• GRADMAN AH, SCHMIEDER RE, LINS RL, NUSSBERGER J, CHIANG Y, BEDIGIAN MP: Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation (2005) 111(8):1012-1018.
   PubMed Web of Science ®Google Scholar
• BAKRIS GL, BANK AJ, KASS DA, NEUTEL JM, PRESTON RA, OPARIL S: Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process. Am. J. Hypertens. (2004) 17(12 Pt 2):23S-30S.
   PubMed Web of Science ®Google Scholar
• HARTOG JW, SMIT AJ, VAN SON WJ et al.: Advanced glycation end products in kidney transplant patients: a putative role in the development of chronic renal transplant dysfunction. J. Kidney. Dis. (2004) 43(6):966-975.
   PubMedGoogle Scholar
• PADI SS, CHOPRA K: Salvage of cyclosporine A-induced oxidative stress and renal dysfunction by carvedilol. Nephron. (2002) 92(3):685-692.
   PubMed Web of Science ®Google Scholar
• HRICIK DE, WU YC, SCHULAK A, FRIEDLANDER MA: Disparate changes in plasma and tissue pentosidine levels after kidney and kidney–pancreas transplantation. Clin. Transplant. (1996) 10(6 Pt 1):568-573.
   PubMedGoogle Scholar
• RAJ DS, LIM G, LEVI M, QUALLS C, JAIN SK: Advanced glycation end products and oxidative stress are increased in chronic allograft nephropathy. Am. J. Kidney. Dis. (2004) 43(1):154-160.
   PubMed Web of Science ®Google Scholar
• SIMONSON MS: Endothelins: multifunctional renal peptides. Physiol. Rev. (1993) 73(2):375-411.
   PubMed Web of Science ®Google Scholar
• KOWALA MC, MURUGESAN N, TELLEW J et al.: Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension Pharmacol. Exp. Ther. (2004) 309(1):275-284.
   PubMed Web of Science ®Google Scholar
• MOHACSI A, MAGYAR J, TAMAS B, NANASI PP: Effects of endothelins on cardiac and vascular cells: new therapeutic target for the future? Curr. Vasc. Pharmacol. (2004) 2(1):53-63.
   PubMedGoogle Scholar
• VANECKOVA I, KRAMER HJ, BACKER A, VERNEROVA Z, OPOCENSKY M, CERVENKA L: Early endothelin-A receptor blockade decreases blood pressure and ameliorates end-organ damage in homozygous Ren-2 rats. Hypertension (2005) 46(4):969-974.
   PubMed Web of Science ®Google Scholar
• HERIZI A, JOVER B, BOURIQUET N, MIMRAN A: Prevention of the cardiovascular and renal effects of angiotensin II by endothelin blockade. Hypertension (1998) 31(1):10-14.
   PubMed Web of Science ®Google Scholar
• HAMMAD FT, WHEATLEY AM, DAVIS G: Role of endothelin ET(A) receptor antagonism in the post transplant renal response to angiotensin II in the rat. Exp. Physiol. (2001) 86(3):365-372.
   PubMedGoogle Scholar
• BUNCHMAN TE, BROOKSHIRE CA: Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells. Clin. Invest. (1991) 88(1):310-314.
   Google Scholar
• PASSAUER J, LASSIG G, BUSSEMAKER E, PISTROSCH F, GROSS P: Reduced endothelin-1- and nitric oxide-mediated arteriolar tone in hypertensive renal transplant recipients. Kidney Int. (2004) 65(5):1782-1789.
   PubMedGoogle Scholar
• WILEY KE: DAVENPORT AP: Nitric oxide-mediated modulation of the endothelin-1 signalling pathway in the human cardiovascular system. Br. J. Pharmacol. (2001) 132(1):213-220.
   PubMedGoogle Scholar
• KNOLL T, OLTERSDORF J, GOTTMANN U et al.: Influence of acute selective endothelin-receptor-A blockade on renal hemodynamics in a rat model of chronic allograft rejection. Transpl. Int. (2003) 16(6):425-429.
   PubMedGoogle Scholar
• JUKEMA JW, VAN DER HOORN JW: Amlodipine and atorvastatin in atherosclerosis: a review of the potential of combination therapy. Expert Opin. Pharmacother. (2004) 5(2):459-468.
   PubMed Web of Science ®Google Scholar
• FRISHMAN WH, ZUCKERMAN AL: Amlodipine/atorvastatin: the first cross risk factor polypill for the prevention and treatment of cardiovascular disease. Expert Rev. Cardiovasc. Ther. (2004) 2(5):675-681.
   PubMedGoogle Scholar
• SEGURA J, GARCIA-DONAIRE JA, RUILOPE LM: Calcium channel blockers and renal protection: insights from the latest clinical trials. J. Am. Soc. Nephrol. (2005) 16(Suppl 1):S64-S66.
   Google Scholar
• LENTINE KL, BRENNAN DC: Statin use after renal transplantation: a systematic quality review of trial-based evidence. Nephrol. Dial. Transplant. (2004) 19(9):2378-2386.
   PubMedGoogle Scholar
• JAMERSON KA, NWOSE O, JEAN-LOUIS L, SCHOFIELD L, PURKAYASTHA D, BARON M: Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am. J. Hypertens. (2004) 17(6):495-501.
   PubMed Web of Science ®Google Scholar
• ERSOY A: Seeking new immunosuppressive regimens in kidney transplantation. Turkiye Klinikleri. J. Surg. Med. Sci. (In press).
   Google Scholar
• ZHANG R, LESLIE B, BOUDREAUX JP, FREY D, REISIN E: Hypertension after kidney transplantation: impact, pathogenesis and therapy. Am. J. Med. Sci. (2003) 325(4):202-208.
   PubMedGoogle Scholar
• KUYPERS DR: Benefit–risk assessment of sirolimus in renal transplantation. Drug. Saf. (2005) 28(2):153-181.
   PubMed Web of Science ®Google Scholar
• MULAY AV, HUSSAIN N, FERGUSSON D, KNOLL GA: Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am. J. Transplant. (2005) 5(7):1748-1756.
   PubMed Web of Science ®Google Scholar
• VEENSTRA DL, BEST JH, HORNBERGER J, SULLIVAN SD, HRICIK DE: Incidence and long-term cost of steroid-related side effects after renal transplantation. Am. J. Kidney Dis. (1999) 33(5):829-839.
   PubMed Web of Science ®Google Scholar
• MAILLOUX LU, LEVEY AS: Hypertension in patients with chronic renal disease. Am. J. Kidney Dis. (1998) 32(5 Suppl. 3):S120-S141.
   PubMed Web of Science ®Google Scholar
• BAKRIS GL, WILLIAMS M, DWORKIN L et al.: Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am. J. Kidney Dis. (2000) 36(3):646-661.
   PubMed Web of Science ®Google Scholar
• JONES JK, GORKIN L, LIAN JF, STAFFA JA, FLETCHER AP: Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. Br. Med. J. (1995) 311(7000):293-295.
   PubMed Web of Science ®Google Scholar